Document is current
Any future updates will be listed below
-
Authors
Hickey, Conor
Gueron, Beatrice
Schmidt, Fabian
Tyas, Emma https://orcid.org/0009-0002-6984-1425
Binowski, Grzegorz
Pivonello, Rosario https://orcid.org/0000-0002-9632-1348
-
Funding
Funding for this research was provided by:
Recordati Rare Diseases
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 30 April 2025
First Online: 29 May 2025
Declarations
:
: Rosario Pivonello has received research funding from Recordati AG, Corcept Therapeutics, Strongbridge Biopharma, Neurocrine Biosciences, Spruce Biosciences; and served as a consultant for Corcept Therapeutics, Recordati AG, Crinetics Pharmaceuticals, and H. Lundbeck A/S. Beatrice Gueron and Fabian Schmidt are employees of Recordati Rare Diseases. Grzegorz Binowski served as a consultant to Recordati AG. Conor Hickey and Emma Tyas are employees of Lumanity, which received research funding from Recordati Rare Diseases for this study.
: This research was based on previously conducted studies and does not contain any new studies performed by any of the authors with human participants or animals. The LINC-3 and LINC-4 clinical trials were conducted in accordance with the Declaration of Helsinki, and study protocols were approved by independent ethics committees/institutional review boards. The PROMPT clinical trial was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.
